Evidence mapPaperPMID 40071198Full record

ReviewClinical, cosmetic and investigational dermatology2025

Potential Applications of Chitosan in Seborrheic Dermatitis and Other Skin Diseases: A Comprehensive Review.

Youting Liu, Jianli Shang, Yong Chen, Xiaoyue Feng

Abstract readReview
In one paragraph

Review in Clinical, cosmetic and investigational dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Youting Liu *Beijing Uproven Medical Technology Co., LTD., Beijing, People's Republic of China.ORCID 0009-0003-2732-2376
Jianli Shang *Beijing Uproven Medical Technology Co., LTD., Beijing, People's Republic of China.ORCID 0009-0007-2841-3033
Yong ChenBeijing Uproven Medical Technology Co., LTD., Beijing, People's Republic of China.ORCID 0009-0009-3113-6449
Xiaoyue FengBeijing Uproven Medical Technology Co., LTD., Beijing, People's Republic of China.ORCID 0000-0002-7177-018X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This review article explores the potential applications of chitosan, a natural polysaccharide derived from crustacean shells, in the treatment of seborrheic dermatitis (SD) and other skin diseases. SD is a common chronic inflammatory skin condition characterized by erythema, scaling, itching, and an oily appearance, predominantly affecting areas rich in sebaceous glands. Current treatments, including antifungal agents, corticosteroids, and calcineurin inhibitors, offer symptomatic relief but have limitations in long-term use due to side effects and resistance issues. Chitosan exhibits excellent biocompatibility, biodegradability, and broad-spectrum antibacterial properties, making it a promising candidate for SD treatment. This review highlights chitosan's multifunctional properties such as antimicrobial, anti-inflammatory, sebum-regulating, and barrier-enhancing effects, which are closely related to the pathogenesis of SD. Additionally, the article summarizes the applications of chitosan in other skin conditions, including wound healing, infectious skin diseases, and atopic dermatitis, demonstrating its broad therapeutic potential. Through this comprehensive evaluation, the review aims to provide a theoretical foundation for clinical research on chitosan in SD and support the development of new, safer, and more effective treatment options for various skin conditions.

Indexed as

chitosanother skin diseasespotential applicationseborrheic dermatitis

Identifiers

PMID40071198
PMCPMC11894430

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.